Parkinson's Europe’s Post

🔖 Interesting article about diversity in #clinical #trials, and how we can enhance inclusivity for more effective and equitable healthcare solutions

In these past 4 years, I have come to love the healthcare industry. I love thr collaboration, the innovation, and the motivation to achieve better outcomes for patients. Here is a list of the medical breakthroughs in 2024. #healthcare #innovation

It's estimated that less than 1% of clinical trials meaningfully and actively engage patients in any part of the research process (source in article). Urgent transformation is essential to make studies more patient-oriented. Medable's VP of Patient and Site Success, Jena Daniels, shares how stakeholders can create a clinical research environment that prioritizes not just the success of the trial but the experience of the people who make that success possible. Read here: https://lnkd.in/ejfJkEUf ________ Michelle Longmire, Tim Smith, Andrew Mackinnon, Alison Holland, Pamela Tenaerts, MD, MBA #clinicaltrials #clinicalresearch #healthcare #patientexperience

The Clinical Outcomes, Analytics and Research team at Prime Therapeutics has been hard at work! Here is a quick view into how my team has worked to enrich data to create proxies for social determinants of health. #SDOH #PrimeTherapeutics #ForwardThinking https://lnkd.in/eiVC3mwT

🌐 Latest Alzheimer's Disease Drug Development in Clinical Trials 🌐 The 2024 Alzheimer's Disease Drug Development Pipeline report highlights significant progress and challenges in the field. Authored by Dr. Jeffrey Cummings and published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, the report notes 164 active trials and 127 unique treatments. Bases on this review paper, it shows key findings include:76% of the treatments are disease-modifying, aiming to slow memory decline. 34% are biological therapies administered intravenously.12% are cognitive enhancers.13% target behavioral symptoms like agitation.31% are repurposed drugs initially developed for other diseases. For a detailed read, you can access the full report here or learn more from the following link. https://lnkd.in/g9KESpYN In addition, I have highlighted the current ongoing studies that are recruiting subjects. Over 20 trials are actively running and enrolling subjects. https://lnkd.in/gWSPq8JH #ClinicalTrials #CRO #Alzheimer #CNRRrsearch #씨엔알리서치 #임상시험 #알츠하이머

Patients are increasingly vocal about their desire for improved access to clinical trials and are calling for better ways to learn about available trials and seeking more support to participate in them. Industry has a crucial role to play in raising public awareness and tailoring communication about the benefits of clinical trials to the communities that will benefit the most from them. Read our full article to see Baringa's insights and recommendations for scaling patient engagement across R&D. https://lnkd.in/enpiZPnK

AccendoWave - A Pain #Data Company Despite decades of work and recent progress—including passage of the Food and Drug Omnibus Reform Act of 2023, which established legislative mandates for increasing clinical trial diversity—there remains a need for collective action across sectors and organizations to align on goals for system-wide, sustainable change. A Top 4 Global Health Equity Solution and Top 15 Global Remote Monitoring Company, AccendoWave, benchmarks objective brain wave pain data (specialty, gender, age) and has nine #pain databases: Emergency Department, Maternal Health, Oncology, MSK, Medical Surgical, ICU, #Women, Adults, Seniors to eliminate bias, improve outcomes and reduce health care costs. If desired, AccendoWave can also create customized pain databases for partners that can be accessed on the Datavant platform.

Thrilled to see @Health Tech World sharing the results of this landmark survey on chronic condition patients and #clinicaltrials! The findings are eye-opening: patients are eager to participate—a powerful signal that it’s time to break down barriers to trial access and engagement. This shift could be a game-changer for patient-centric research and the future of clinical innovation. #realworlddata #clinicaltrialrecruitment #crowdsourcing Check out the full article here: https://lnkd.in/dVtCrUB8

While this is news coverage from the US, I don’t think the headline really answers the question it poses. There are several reasons I think the drug is off to slow start including prelim cost, poor health system preparedness particularly imaging needs, and effectiveness vs cost-benefit. If you want to dive in, more details below…. Partly it was the extremely high cost that its predecessor Aducanumab was introduced to the market at (subsequently prices slashed and then completely discontinued) which created major sticker shock given the number of people expected to access it. Secondly, most health systems are woefully underprepared to adequately screen and manage patients on the drug given the number of imaging tests they would need to monitor for side effects - the more serious ones being ARIA which includes brain swelling or bleeding. With limited MRI machines patients would need to wait much longer than the protocol time would recommend if they even get access to them at all. We haven’t even touched on really how under prepared physicians are to diagnose appropriately that early. And lastly the window of effect is in essence to slow down memory decline by about five months. To some patients, this is a huge window of opportunity, for others the cost benefit may not be worth it.

🚨 A pioneering analysis of #EHR data from Optum has shown that it's finally possible to quantify the risk-to-benefit ratio of prescribing glucocorticoids. 🚨 Learn how, utilizing the Steritas GTI-MD, a team comprised of researchers from Harvard Medical School, argenx, ZS and Steritas achieved these groundbreaking results: https://hubs.li/Q02yxcts0 #SteritasGTI #ClinicalResearch #HEOR #ClinicalTrials #ClinicalData #Autoimmune #AutoimmuneDisease #PatientCare #Healthcare #TreatmentPlans #TreatmentAlternatives